View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Beyond Air to Participate in the 38th Annual Roth Conference in March

Beyond Air to Participate in the 38th Annual Roth Conference in March GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman & Chief Executive Officer of Beyond Air, will participate in the 38th Annual Roth Conference being held March 22nd to 24th in Laguna Niguel, CA. 38th Annual Roth ConferenceFormat:Fireside chat and one-on-one meeti...

 PRESS RELEASE

Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading under “FLNA” effective March 11, 2026 AUSTIN, Texas, March 10, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA) today announced the rebranding of the Company, with a name change to Filana Therapeutics, Inc. (“Filana Therapeutics”, or the “Company”). The new name and corporate brand reflect the Company’s strategi...

 PRESS RELEASE

Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Su...

Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals Ltd. (“XTL”) relating to Beyond Air’s NeuroNOS subsidiary has been terminated. The companies entered into a letter of i...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Harvard Bioscience Announces Reverse Stock Split

Harvard Bioscience Announces Reverse Stock Split Harvard Bioscience’s common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a global leader in life science research tools, today announced that its board of directors approved the Company’s 1-for-10 reverse stock split (the “Reverse Split”) of the Company’s common stock, par value $0.01 per share. The Reverse Split was approved by the stockholders of the Company at a spec...

 PRESS RELEASE

AerSale® Reports Fourth Quarter and Full Year 2025 Results

AerSale® Reports Fourth Quarter and Full Year 2025 Results Fourth Quarter 2025 Highlights Revenue of $90.9 million versus $94.7 million in the prior year periodGAAP net income of $5.4 million versus GAAP net income of $2.7 million in the prior year periodAdjusted net income1 of $7.5 million versus adjusted net income of $4.8 million in the prior year periodAdjusted EBITDA1 of $15.2 million versus Adjusted EBITDA of $13.0 million in the prior year periodFlight equipment sales consisted of four engines compared to six engines in the prior year periodFeedstock acquisitions of $15.4 million i...

 PRESS RELEASE

Bioventus Announces Fourth Quarter and Full Year 2025 Financial Result...

Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0%Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year periodNon-GAAP earnings* of $0.24 per diluted shareFourth quarter cash from operations of $38.0 million increased 97%2026 financial guidance reflects continued above-market revenue growth, higher earnings and robust cash generation DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”),...

FTAI Aviation Ltd: 1 director

A director at FTAI Aviation Ltd sold 10,000 shares at 303.350USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

PENN Entertainment, Inc.: Update to credit analysis following outlook ...

Our credit view of this issuer reflects its high leverage, against its scale and geographic diversification.

 PRESS RELEASE

Texas Capital Earns Best Bank Award for Middle Market Banking in the U...

Texas Capital Earns Best Bank Award for Middle Market Banking in the U.S. (West) Clients cite strong satisfaction with the firm’s middle market banking DALLAS, March 03, 2026 (GLOBE NEWSWIRE) -- Texas Capital announced today that it has been named as a Best Bank – Likelihood to Recommend for Middle Market Banking in the U.S. (West) by Crisil Coalition Greenwich, recognizing the firm’s approach to serving middle market companies through its client-focused, full-service banking platform. Texas Capital serves small business, middle market and corporate clients across industries and geogra...

 PRESS RELEASE

Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Foru...

Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer, will be participating in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17th. A fireside chat will be broadcast from the company’s at 2:15pm ET that day. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website . About...

 PRESS RELEASE

Advantage Solutions Reports Fourth Quarter and Full Year 2025 Results

Advantage Solutions Reports Fourth Quarter and Full Year 2025 Results   Strong cash flow performance resulted in ending the quarter with $241 million of cash, up $40 million sequentially    Completion of non-core divestitures, planned debt refinancing and upcoming reverse stock split    Expect flat to up low-single digit revenue growth in 2026, Adjusted EBITDA flat to down mid-single digits    ST. LOUIS, March 03, 2026 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage,” “Advantage Solutions,” the “Company,” “we,” or “our”), a leading business solutions provider to ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 28, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch